ASX 200 midday update: Metcash and Imugene jump, Evolution downgrades guidance again

The ASX 200 is having a great day on Monday…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

At lunch on Monday, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a strong gain. The benchmark index is currently up 1.6% to 6,686.1 points.

Here's what is happening on the ASX 200 today:

Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices

Image source: Getty Images

Metcash jumps on FY 2022 results

The Metcash Limited (ASX: MTS) share price is storming higher today after the wholesaler smashed the market's FY 2022 earnings estimates. Metcash reported an 18.6% increase in underlying net profit after tax to $299.6 million. This compares favourably to the market consensus estimate of an underlying profit of $279 million. Solid growth from all sides of the business drove the strong result.

Imugene shares rocket on study results

The Imugene Limited (ASX: IMU) share price is rocketing higher today following the release of study results. This morning the immuno-oncology company revealed positive final overall survival data from its Phase 2 study of HER-Vaxx following the analysis of safety and efficacy data. This study was in Her-2/Neu overexpressing advanced/metastatic gastric/GEJ cancer.

Evolution shares crash on third FY22 guidance downgrade

The Evolution Mining Ltd (ASX: EVN) share price is having a day to forget. This gold miner's shares have been crushed after it downgraded its FY 2022 guidance yet again. Evolution now expects FY 2022 gold production to be around 640,000 ounces. This compares to its original guidance of 700,000 to 760,000 ounces, which was then reduced twice, most recently to 650,000 ounces. Costs are also expected to be higher than expected and future production will be lower than guided to.

Best and worst ASX 200 performers

The best performer on the ASX 200 index on Monday by some distance is the Imugene share price with a 40% gain. This follows the release of positive study results. Going the other way, the Evolution share price is far and away the worst performer with a 20% decline. This has been driven by its bleak guidance update.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Share Market News

Testing again

Read more »

Share Market News

Aaron Test 2

Read more »

Share Market News

Aaron Test

Read more »

Share Market News

JP Test

Read more »

Share Market News

JP Test

Read more »

Portrait of Discovery Fund portfolio managers Mark Devcich and Chris Bainbridge
Share Market News

Test

Portfolio managers Mark Devcich (left) and Chris Bainbridge. Image source: Discovery Fund test test

Read more »

a man in a hoodie grins slyly as he sits with his hands poised on a keyboard. He is superimposed with a graphic image of a computer screen asking for a password, suggesting he is a hacker.
Share Market News

Another ASX 200 company has been hit with a cyber incident. Here's what we know

Hackers have breached the systems of this ASX 200 company.

Read more »

a woman
Broker Notes

5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

Read more »